

## LHFPL4 (C-17): sc-99499

### BACKGROUND

The development of lipomas, benign tumors composed of fatty tissues, have been linked to breakpoints in the HMGI-C gene. LHFPL4 (lipoma HMGIC fusion partner) is a 200 amino acid multi-pass membrane protein that acts as a fusion partner with HMGI-C in a lipoma with the translocation t(12;13)(q13-q15;q12). As a LHFPL4 family member, LHFPL5 (lipoma HMGIC fusion partner-like 4 protein) is a 247 amino acid multi-pass membrane protein that is encoded by a gene which is found to be methylated in 55% of cervical cancers. This suggests that LHFPL4 is a novel methylation target specific for cervical cancer and may be evaluated for early detection and risk prediction. LHFPL4 shares 62% sequence similarity with LHFPL5, a protein which has been linked to normal function of the human cochlea. There are two isoforms of LHFPL4 that are produced as a result of alternative splicing events.

### REFERENCES

- Petit, M.M., Schoenmakers, E.F., Huysmans, C., Geurts, J.M., Mandahl, N. and Van de Ven, W.J. 1999. LHFPL4, a novel translocation partner gene of HMGI-C in a lipoma, is a member of a new family of LHFPL-like genes. *Genomics* 57: 438-441.
- Rogalla, P., Lemke, I. and Bullerdiek, J. 2002. Absence of HMGI-C-LHFPL4 fusion in pulmonary chondroid hamartomas with aberrations involving chromosomal regions 12q13 through 15 and 13q12 through q14. *Cancer Genet. Cytogenet.* 133: 90-93.
- Longo-Guess, C.M., Gagnon, L.H., Cook, S.A., Wu, J., Zheng, Q.Y. and Johnson, K.R. 2005. A missense mutation in the previously undescribed gene *Tmhs* underlies deafness in hurry-scurry (*hscy*) mice. *Proc. Natl. Acad. Sci. USA* 102: 7894-7899.
- Nilsson, M., Mertens, F., Höglund, M., Mandahl, N. and Panagopoulos, I. 2006. Truncation and fusion of HMGA2 in lipomas with rearrangements of 5q32→q33 and 12q14→q15. *Cytogenet. Genome Res.* 112: 60-66.
- Kalay, E., Li, Y., Uzumcu, A., Uyguner, O., Collin, R.W., Caylan, R., Ulubil-Emiroglu, M., Kersten, F.F., Hafiz, G., van Wijk, E., Kayserili, H., Rohmann, E., et al. 2006. Mutations in the lipoma HMGI-C fusion partner-like 5 (LHFPL5) gene cause autosomal recessive nonsyndromic hearing loss. *Hum. Mutat.* 27: 633-639.
- Shabbir, M.I., Ahmed, Z.M., Khan, S.Y., Riazuddin, S., Waryah, A.M., Khan, S.N., Camps, R.D., Ghosh, M., Kabra, M., Belyantseva, I.A., Friedman, T.B. and Riazuddin, S. 2006. Mutations of human TMHS cause recessively inherited non-syndromic hearing loss. *J. Med. Genet.* 43: 634-640.
- Online Mendelian Inheritance in Man, OMIM™. 2006. Johns Hopkins University, Baltimore, MD. MIM Number: 610240. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
- Wang, S.S., Smiraglia, D.J., Wu, Y.Z., Ghosh, S., Rader, J.S., Cho, K.R., Bonfiglio, T.A., Nayar, R., Plass, C. and Sherman, M.E. 2008. Identification of novel methylation markers in cervical cancer using restriction landmark genomic scanning. *Cancer Res.* 68: 2489-2497.

### CHROMOSOMAL LOCATION

Genetic locus: LHFPL4 (human) mapping to 3p25.3; Lhfpl4 (mouse) mapping to 6 E3.

### SOURCE

LHFPL4 (C-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping near the C-terminus of LHFPL4 of human origin.

### PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-99499 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

### APPLICATIONS

LHFPL4 (C-17) is recommended for detection of LHFPL4 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

LHFPL4 (C-17) is also recommended for detection of LHFPL4 in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for LHFPL4 siRNA (h): sc-78176, LHFPL4 siRNA (m): sc-146723, LHFPL4 shRNA Plasmid (h): sc-78176-SH, LHFPL4 shRNA Plasmid (m): sc-146723-SH, LHFPL4 shRNA (h) Lentiviral Particles: sc-78176-V and LHFPL4 shRNA (m) Lentiviral Particles: sc-146723-V.

Molecular Weight of LHFPL4: 27 kDa.

### RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

### STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### RESEARCH USE

For research use only, not for use in diagnostic procedures.

### PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.